Nucleoside and nucleotide analogs have played significant roles in antiviral therapies and are valued for their impressive potency and high barrier to resistance. They have been approved for treatment of herpes simplex virus-1, HIV, HBV, HCV, and influenza, and new drugs are being developed for the treatment of RSV, Ebola, coronavirus MERS, and other emerging viruses. However, this class of compounds has also experienced a high attrition rate in clinical trials due to toxicity. In this review, we discuss the utility of different biochemical and cell-based assays and provide recommendations for assessing toxicity liability before entering animal toxicity studies.

Joy Y Feng

Antiviral chemistry & chemotherapy

Antiviral Chemistry & Chemotherapy publishes the results of original research concerned with the biochemistry, mode of action, chemistry, pharmacology and virology of antiviral compounds. Manuscripts dealing with molecular biology, animal models and vaccines are welcome.     The journal also publishes reviews, pointers, short communications and correspondence.

Antiviral Chemistry and Chemotherapy publishes original research results related to the biochemistry, mode of action, chemistry, pharmacology, and virology of antiviral compounds. Manuscripts addressing molecular biology, animal models, and vaccines are also welcome. The journal additionally publishes reviews, pointers, short communications, and correspondence.

《Antiviral Chemistry and Chemotherapy》期刊致力于发表与抗病毒化合物的生物化学、作用机制、化学、药理学和病毒学相关的原创研究成果。欢迎提交涉及分子生物学、动物模型和疫苗的手稿。此外，期刊还接受综述、指引、简短通讯和信函的投稿。

Addressing the selectivity and toxicity of antiviral nucleosides

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info